Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called T-cell lymphoma, which includes specific subtypes such as Cutaneous T-cell lymphoma and Mycosis fungoides. These are advanced forms of cancer that affect the skin and other parts of the body. The treatment being tested in this study is a medication called Lacutamab, also known by its code name IPH4102. Lacutamab is a type of protein treatment known as a monoclonal antibody, which is designed to target and attack cancer cells. The study will explore the effects of Lacutamab when used alone or in combination with chemotherapy.

The purpose of this study is to evaluate how well patients respond to the treatment. Participants will receive Lacutamab through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the participants over a period to see how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of Lacutamab. The study will also assess the safety of the treatment and any side effects that may occur.

Throughout the study, researchers will collect information on how the treatment affects the participants' quality of life and overall health. This includes monitoring any changes in symptoms and conducting regular health checks. The study aims to provide valuable insights into the effectiveness of Lacutamab for treating advanced T-cell lymphoma and to determine if it can be a beneficial treatment option for patients with this type of cancer.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the patient will undergo a screening process to confirm eligibility. This includes a review of medical history and a physical examination.

    A skin biopsy may be required to assess the condition of the skin lesions.

  2. Step 2

    Treatment initiation

    The patient will begin treatment with Lacutamab, administered as an intravenous infusion. The specific dosage and frequency will be determined by the study protocol.

    A minimum wash-out period of 3 weeks is required between the last dose of any prior systemic therapy and the first dose of Lacutamab.

  3. Step 3

    Treatment phase

    During the treatment phase, the patient will receive regular infusions of Lacutamab. The duration and frequency of these infusions will be specified in the study protocol.

    The patient's response to the treatment will be monitored through regular assessments, including blood tests and imaging studies.

  4. Step 4

    Safety and efficacy assessments

    The study will evaluate the objective response rate (ORR), which measures the proportion of patients with a complete or partial response to the treatment.

    Safety assessments will include monitoring for adverse events, changes in laboratory evaluations, and vital signs.

  5. Step 5

    Quality of life assessments

    The patient's quality of life will be assessed using a questionnaire and a visual analog scale (VAS) for pruritus.

    These assessments aim to understand the impact of the treatment on the patient's daily life and well-being.

  6. Step 6

    End of treatment

    The treatment phase will conclude as per the study protocol, or if the patient experiences disease progression or unacceptable side effects.

    Follow-up assessments may be conducted to evaluate the long-term effects of the treatment.

Who can join the trial?

15 criteria

  • Patients with **Sézary Syndrome (SS)** must have a type of cancer that has come back or not responded to treatment, specifically stage IVA or IVB, and have tried at least two different treatments before.
  • Patients with **Mycosis Fungoides (MF)** must have a type of cancer that has come back or not responded to treatment, specifically stage IB, IIA, IIB, III, or IV, and have tried at least two different treatments before.
  • Patients must be able to have at least one skin sample taken for testing at the start of the study.
  • Patients must be at least 18 years old.
  • Patients must have a **performance status** of 2 or less, which means they should be able to carry out daily activities with some help.
  • Patients must wait at least 3 weeks after their last treatment before starting the study treatment.
  • Patients should have recovered from any side effects of previous treatments, except for hair loss, to a mild level.
  • Patients must have certain blood test results within normal ranges, such as hemoglobin, neutrophil count, and platelets.
  • Patients must have certain liver and kidney function test results within normal ranges.
  • Women who can become pregnant must have a negative pregnancy test before starting the study.
  • Women who can become pregnant and all men must agree to use birth control during the study and for 9 months after the last dose of the study drug.
  • Patients must sign a consent form agreeing to participate in the study.
  • Patients with SS must have had treatment with a specific drug called **mogamulizumab** before.
  • Patients with SS must have a certain level of cancer cells in their blood, confirmed by a test called **flow cytometry**.
  • For MF patients in a specific group, their skin must show a certain protein called **KIR3DL2** in at least one skin lesion, confirmed by a test called **IHC**.

Who cannot join the trial?

10 criteria

  • Patients with other types of cancer that are not the specific T-Cell Lymphomas being studied.
  • Patients who have not experienced a return or worsening of their T-Cell Lymphoma after treatment.
  • Patients with serious infections that are not controlled or treated.
  • Patients with significant heart problems that could affect their health during the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who are unable to follow the study procedures or attend the required visits.
  • Patients who have participated in another clinical trial recently.
  • Patients with a history of severe allergic reactions to similar treatments.
  • Patients with certain autoimmune diseases, which are conditions where the immune system attacks the body.
  • Patients with liver or kidney problems that are severe.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • IPH4102

    is a medication being studied for its potential to treat advanced T-cell lymphoma. It is designed to target a specific protein on the surface of cancer cells, which may help the immune system recognize and attack these cells more effectively. This medication is being tested alone to see how well it works in shrinking or controlling the cancer.

  • Chemotherapy

    is a type of cancer treatment that uses drugs to destroy cancer cells. In this trial, chemotherapy is combined with IPH4102 to evaluate if the combination is more effective than using IPH4102 alone. Chemotherapy works by stopping the growth of cancer cells, which can help reduce the size of tumors and slow the progression of the disease.

What is already known about the treatment

IPH4102 – This medication is administered intravenously and is currently being studied in clinical trials for its effectiveness in treating advanced T-cell lymphomas, including specific subtypes like Sézary Syndrome and Mycosis Fungoides. It is in the experimental phase and is not yet widely recognized in medical literature as a standard treatment. The main therapeutic indication is for patients with relapsed or refractory forms of these lymphomas. At the molecular level, IPH4102 works by targeting and binding to a specific receptor on the surface of cancer cells, which helps the immune system to identify and destroy these cells. It is classified as a monoclonal antibody, a type of targeted cancer therapy.

Investigated diseases

Cutaneous T-Cell Lymphoma (CTCL) – This is a type of cancer that begins in the T-cells, which are part of the immune system, and primarily affects the skin. It often presents as patches, plaques, or tumors on the skin and can cause itching and redness. Over time, the disease may progress to involve the lymph nodes, blood, and internal organs. CTCL includes various subtypes, such as Mycosis Fungoides and Sézary Syndrome, each with distinct characteristics. Mycosis Fungoides typically starts with skin lesions that may evolve into tumors, while Sézary Syndrome is characterized by widespread skin involvement and the presence of malignant T-cells in the blood. The progression of CTCL can vary significantly among individuals, with some experiencing slow progression and others more rapid changes.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-507777-18-00Protocol codeIPH4102-201Estimated enrolment174 patientsSponsorInnate Pharma

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).